Cognition Therapeutics CEO to Present Zervimesine Progress at H.C. Wainwright Conference
Event summary
- Cognition Therapeutics CEO Lisa Ricciardi will present at the H.C. Wainwright Global Investment Conference on September 15, 2026.
- Presentation will focus on progress of zervimesine for Alzheimer's disease and dementia with Lewy bodies (DLB).
- Zervimesine has completed Phase 2 trials in DLB, Alzheimer’s disease, and geographic atrophy.
- Company has raised nearly $200 million in NIH and related foundation grants.
- Live webcast available on Cognition’s Investor Relations page.
The big picture
Cognition Therapeutics is positioning itself as a key player in neurodegenerative disease treatment, with zervimesine as its lead candidate. The upcoming presentation at the H.C. Wainwright Conference highlights the company’s focus on translating early-phase clinical success into broader therapeutic applications. The biopharmaceutical sector continues to prioritize innovative treatments for Alzheimer’s and related disorders, with significant investor interest in pipeline progress.
What we're watching
- Clinical Progress
- Whether Phase 2 efficacy signals in DLB will translate into late-stage trial success.
- Regulatory Pathway
- The pace at which zervimesine advances through regulatory approvals for Alzheimer’s and DLB.
- Funding Strategy
- How Cognition Therapeutics will sustain its $200 million in grant funding for future trials.